Research Topics
Species | Jonathan BerekSummaryAffiliation: Stanford University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Personalizing CA125 levels for ovarian cancer screeningOliver Dorigo
Department of Obstetrics and Gynecology, The UCLA David Geffen School of Medicine, Los Angeles, CA, USA
Cancer Prev Res (Phila) 4:1356-9. 2011..The data suggest that CA125 cutoff points might have to be stratified for subgroups of patients to reduce false-positive results. These intriguing observations will need to be validated in future screening trials for ovarian cancer...- Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancerJonathan S Berek
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Women s Cancer Center, Stanford Cancer Center, Stanford, California, USA
Obstet Gynecol 116:733-43. 2010..Conversely, women at high risk of ovarian cancer should undergo risk-reducing bilateral salpingo-oophorectomy... - Lymph node-positive stage IIIC ovarian cancer: a separate entity?Jonathan S Berek
Department of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
Int J Gynecol Cancer 19:S18-20. 2009..Patients undergoing cytoreductive surgery for advanced-stage ovarian cancer undergo concomitant retroperitoneal lymphadenectomy in an effort to improve their survival... - Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancerJonathan Berek
Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
J Clin Oncol 27:418-25. 2009.... - CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancerJonathan S Berek
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA, USA
J Immunother 31:207-14. 2008..Velocity of CA125 rise at relapse is a highly significant predictor of survival after relapse... 
Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancerSanaz Memarzadeh
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095 1740, USA
Obstet Gynecol 102:612-9. 2003..To estimate the impact of parametrial lymphovascular and perineural involvement on nodal metastasis and failure pattern of women with early-stage, surgically treated cervical cancer...- Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 womenMallory Zhang
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
Gynecol Oncol 104:396-400. 2007..To evaluate prognostic factors that impact on the survival of women with ovarian sex cord stromal tumors (SCST)... - Association of lymphadenectomy and survival in stage I ovarian cancer patientsJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305, USA
Obstet Gynecol 109:12-9. 2007..To estimate the survival impact of lymphadenectomy in women diagnosed with clinical stage I ovarian cancer... - Patterns and progress in ovarian cancer over 14 yearsJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, California 94305, USA
Obstet Gynecol 108:521-8. 2006..To estimate the change in survival rates of women with ovarian cancer during the past 14 years... - Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deathsStefanie M Ueda
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF, School of Medicine and Comprehensive Cancer Center, San Francisco, CA 94143 1702, USA
Am J Obstet Gynecol 198:218.e1-6. 2008..The purpose of this study was to determine factors responsible for the increasing number of deaths from corpus cancer over three time periods... - Vulvar melanoma: a multivariable analysis of 644 patientsValerie E Sugiyama
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, UCSF Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA, USA
Obstet Gynecol 110:296-301. 2007..To determine the prognostic factors associated with the survival of vulvar melanoma patients... - Influence of the gynecologic oncologist on the survival of ovarian cancer patientsJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics, University of California, San Francisco School of Medicine, San Francisco Comprehensive Cancer Center, San Francisco, California 94143 1702, USA
Obstet Gynecol 109:1342-50. 2007..To estimate the influence of gynecologic oncologists on the treatment and outcome of patients with ovarian cancer... - Prognostic factors for uterine cancer in reproductive-aged womenNita Karnik Lee
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California 94143, USA
Obstet Gynecol 109:655-62. 2007..To determine the prognostic factors that influence the survival of younger women diagnosed with uterine cancer... - Biologic and immunologic therapies for ovarian cancerJonathan S Berek
Division of Gynecologic Oncology, David Geffen School of Medicine at University of California Los Angeles, UCLA Center for the Health Sciences, Los Angeles, CA 90095 1740, USA
J Clin Oncol 21:168s-174s. 2003..A phase III study of interferon gamma in combination with first-line chemotherapy is currently ongoing... - The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinomaAnand Parthasarathy
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
Gynecol Oncol 103:1095-9. 2006..06). CONCLUSION: Our data suggest that adjuvant radiotherapy may improve the disease-specific survival of patients with single-node-positive vulvar cancer who underwent a less extensive lymph node resection (<or=12 nodes removed)... - Ovarian conservation at the time of hysterectomy for benign diseaseWilliam H Parker
UCLA School of Medicine, Los Angeles, California, USA
Clin Obstet Gynecol 50:354-61. 2007..Therefore, the decision to perform prophylactic oophorectomy should be approached with great caution for the majority of women who are at low risk of developing ovarian cancer... - Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trialBradley J Monk
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Building 23, Room 107, Orange, CA 92868, USA
Gynecol Oncol 96:721-8. 2005.... - Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancerJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Services, University of California, San Francisco School of Medicine, Helen Diller Family Comprehensive Cancer Center, 94143 1702, USA
Am J Obstet Gynecol 198:216.e1-5. 2008..The purpose of this study was to evaluate the role of surgical staging in patients with grade 1 endometrioid uterine cancer... - Elective oophorectomy in the gynecological patient: when is it desirable?William H Parker
UCLA School of Medicine, Los Angeles, California, USA
Curr Opin Obstet Gynecol 19:350-4. 2007..Oophorectomy is electively performed in approximately 300,000 US women per year who are having hysterectomy for benign disease... - Ovarian conservation at the time of hysterectomy for benign diseaseWilliam H Parker
The David Geffen School of Medicine, University of California, Los Angeles, California, USA
Obstet Gynecol 106:219-26. 2005..Prophylactic oophorectomy is often recommended concurrent with hysterectomy for benign disease. The optimal age for this recommendation in women at average risk for ovarian cancer has not been determined... - Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancerJonathan S Berek
David Geffen School of Medicine at UCLA, Division of Gynecologic Oncology, University of California at Los Angeles, CA 90095 1740, USA
J Clin Oncol 22:3507-16. 2004..To assess oregovomab as consolidation treatment of advanced ovarian cancer and refine the immunotherapeutic strategy for subsequent study... - HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature reviewAmer Karam
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Gynecol Oncol 111:568-71. 2008..The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target... - Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLAJonathan S Berek
Division of Gynecologic Oncology, David Geffen School of Medicine, University of California Los Angeles, UCLA Center for the Health Sciences 24 127, 10833 LeConte Avenue, Los Angeles, CA 90095 1740, USA
Gynecol Oncol 99:153-9. 2005..To retrospectively assess the outcome of patients undergoing pelvic exenteration for recurrent or persistence gynecologic malignancy and the clinical features associated with outcome and survival... - Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapyMory Nouriani
Division of Gynecologic Oncology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Clin Cancer Res 10:2681-6. 2004.... - Intraperitoneal chemotherapy for ovarian cancerChad A Hamilton
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, California 94305, USA
Curr Opin Oncol 18:507-15. 2006..Efforts should continue to facilitate the integration of intraperitoneal treatment into mainstream practice, and future trials should be designed to address lingering controversy surrounding this route of treatment... - Immunotherapy of ovarian cancer with antibodies: a focus on oregovomabJonathan S Berek
David Geffen School of Medicine at UCLA, 24 137 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1740, USA
Expert Opin Biol Ther 4:1159-65. 2004..Additional studies of antigen processing and combination chemo-immunotherapy are ongoing. The treatment shows promise as a potential new addition to the standard care of ovarian cancer... - Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patientsJohn K Chan
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, University of California, San Francisco Comprehensive Cancer Center, California 94143 1702, USA
Cancer 109:2454-60. 2007.... - Cervical cancer: an opportunity to prevent and cureJonathan S Berek
Cancer J 9:325-6. 2003 - Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003 - Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007Alan Ashworth
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
Gynecol Oncol 108:652-7. 2008..As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors... - Monoclonal antibody therapy of ovarian cancerChristopher F Nicodemus
Unither Pharmaceuticals, Inc, 15 Walnut Street, Suite 300, Wellesley Hills, MA 02481 2101, USA
Expert Rev Anticancer Ther 5:87-96. 2005..These antibodies could complement novel small molecules that are also in development... - Elective oophorectomy for benign gynecological disordersDonna Shoupe
Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA
Menopause 14:580-5. 2007..To review the risks and benefits of elective oophorectomy and to make a clinical recommendation for an appropriate age when benefits of this procedure outweigh the risks... - CA125: megadaltons of novel opportunitiesOliver Dorigo
Gynecol Oncol 104:505-7. 2007 - Surgery for ovarian cancer: how to improve survivalRobert E Bristow
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Lancet 367:1558-60. 2006 - Specific keynote: immunological therapy for ovarian cancerJonathan S Berek
David Geffen School of Medicine, University of California at Los Angeles, USA
Gynecol Oncol 88:S105-9; discussion S110-3. 2003
Research Grants
- MENTORING & ADVANCED RESEARCH TRAINING FOR WRHR SCHOLARSJonathan Berek; Fiscal Year: 2007..This cadre of Scholars will be among future leaders in women's reproductive health research in the United States. ..